What to eat after brigatinib/brigatinib resistance

Brigatinib is a drug that targets non-small cell lung cancer (NSCLC) caused by ALK mutations. However, sometimes patients may develop resistance to brigatinib after taking it for a period of time. Once resistance develops, treatment regimens need to be adjusted to provide more effective treatment options. After brigatinib resistance, the following treatment strategies can be considered:

1.Switch to other targeted drugs: A common strategy is to stop brigatinib and start using other targeted drugs, such as crizotinib or alectinib. These drugs can also inhibit ALK fusion proteins and have certain efficacy.

2. Combined treatment with chemotherapy drugs: Another option is to combine treatment with chemotherapy drugs to enhance the therapeutic effect. The use of drug combinations in lung cancer has proven to be effective.One successful example of a combination is brigatinib and itraconazole. Coadministration of brigatinib with itraconazole (a strong CYP3A inhibitor) 200 mg twice daily resulted in an approximately 21% increase in brigatinib plasma concentration and an approximately 101% increase in AUC compared to brigatinib administered at a dose of 90 mg alone.

3. Participate in clinical trials: If other treatment options are ineffective or inapplicable, patients can consider participating in clinical trials targeting drug resistance. These trials are designed to evaluate new treatment options such as novel drugs, targeted therapies, or immunotherapies.

Regardless of which treatment strategy is chosen, the patient's specific situation and the physician's recommendations should be considered when developing a treatment plan. Factors such as drug selection and dosage should be evaluated and decided by a professional physician based on the patient's condition. In addition, patients should actively cooperate with treatment, maintain close communication with their doctors, and promptly report any discomfort or side effects.